CIL 002
Alternative Names: CIL-002Latest Information Update: 29 May 2024
At a glance
- Originator Sanofi
- Developer Cilcare
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hidden hearing loss
Most Recent Events
- 29 May 2024 Cilcare has patent protection for CIL 002, before May 2024 (Cilcare website, May 2024)
- 29 May 2024 Preclinical trials in Hidden hearing loss in France (unspecified route), before May 2024 (Cilcare pipeline, May 2024)